Abstract:<span>Atopic dermatitis (AD) is the long-lasting chronic inflammatory skin condition associated with cutaneous hyper-reactivity and triggered by environmental factors. The attributes of AD include dry skin, pruritus, lichenification and frequent eczematous abrasions. This has a strong heritable aspect and typically occurs with asthma and allergic rhinitis. The complex pathological mechanism behind AD etiology is epidermal barrier destruction resulting in the lack of filaggrin protein that can induce inflammation and T-cell infiltration. T-helper 2 cell-mediated pathways also bear the responsibility of damage to the epidermal barrier. Certain causative factors for AD include microbial imbalance of skin microbiota, immunoglobulin-E-induced sensitization and neuro-inflammation. Numerous beneficial topical and oral treatments have been available to patients and there are even more drugs in the pipeline for the treatment of AD. Topical moisturizers, corticosteroids, anti-inflammatory agents such as calcineurin inhibitors, phototherapy, cAMP-specific 3, 5 half-cyclic phosphodiesterase 4 inhibitors and systemic immunosuppressants are widely available for AD treatments. Different positions and pathways inside the immune system including JAK-STAT, phosphodiesterase 4, aryl hydrocarbon receptor and T-helper 2 cytokines are targeted by above-mentioned drug treatments. Instead of the severe side effects of topical steroids and oral antihistamines, herbal plants and their derived phytoconstituents are commonly used for the treatment of AD. A clear understanding of AD's cellular and molecular pathogenesis through substantial advancement in genetics, skin immunology and psychological factors resulted in advancement of AD management. Therefore, the review highlights the recent advancements in the understanding of clinical features, etiology, pathogenesis, treatment and management and non-adherence to AD treatment.</span>

Biologics in the Treatment of Atopic Dermatitis

Biologic and Small Molecule Therapy in Atopic Dermatitis

Biologics and Oral Small-Molecule Inhibitors for Treatment of Pediatric Atopic Dermatitis: Opportunities and Challenges

Current and Emerging Biologics for Atopic Dermatitis

Emerging Biologic Therapies for the Treatment of Atopic Dermatitis

New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration.

Biologic drugs, a new therapeutic paradigm in moderate-severe atopic dermatitis

Biologics for chronic inflammatory skin diseases: an update for the clinician

Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches

Molecular Biology of Atopic Dermatitis

Current Research on Pathogenesis and Treatment of Atopic Dermatitis

A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis

Therapeutic management of atopic dermatitis

Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies

Update on the Pathogenesis and Therapy of Atopic Dermatitis

Medications for atopic dermatitis

Potential of Bioactive Compounds for Atopic Dermatitis

Molecular Mechanisms of Atopic Dermatitis Pathogenesis

Biologics for pediatric atopic dermatitis: A protocol of a systematic review and meta-analysis

Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors

Pathophysiology of atopic dermatitis: Clinical implications.